Jentashapir Journal of Health Research

Published by: Kowsar

miR-155 Expression in the Serum of Patients with Ductal Carcinoma in Situ (DCIS) of the Breast and Patients with Invasive Ductal Carcinoma (IDC) of the Breast

Bentolhoda Shooshtarian 1 , Javad Mohammadi-asl 2 , * and Lila Kohan 1
Authors Information
1 Department of Biology, Arsanjan Branch, Islamic Azad University, Arsanjan, Iran
2 Cancer, Petroleum and Environmental Pollutants Research Center, Ahvaz Jundishapur University of Medical Sciences (AJUMS), Ahvaz, Iran
Article information
  • Jentashapir Journal of Health Research: April 2017, 8 (2); e62563
  • Published Online: April 30, 2017
  • Article Type: Research Article
  • Received: February 2, 2017
  • Revised: March 5, 2017
  • Accepted: April 2, 2017
  • DOI: 10.5812/jjhr.62563

To Cite: Shooshtarian B, Mohammadi-asl J, Kohan L. miR-155 Expression in the Serum of Patients with Ductal Carcinoma in Situ (DCIS) of the Breast and Patients with Invasive Ductal Carcinoma (IDC) of the Breast, Jentashapir J Health Res. 2017 ; 8(2):e62563. doi: 10.5812/jjhr.62563.

Copyright © 2017, Jentashapir Journal of Health Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013. [PubMed: 21376230].
  • 2. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430-41. doi: 10.1056/NEJMra031301. [PubMed: 15070793].
  • 3. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchio C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57(2):171-92. doi: 10.1111/j.1365-2559.2010.03568.x. [PubMed: 20500230].
  • 4. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A. 2012;109(8):3024-9. doi: 10.1073/pnas.1200010109. [PubMed: 22315424].
  • 5. Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2010;11(7):537-61. doi: 10.2174/138920210793175895. [PubMed: 21532838].
  • 6. Casey MC, Sweeney KJ, Brown JA, Kerin MJ. Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer. Int J Cancer. 2016;139(1):12-22. doi: 10.1002/ijc.29985. [PubMed: 26756433].
  • 7. Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2009;2:89. doi: 10.1186/1756-0500-2-89. [PubMed: 19454029].
  • 8. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005;102(10):3627-32. doi: 10.1073/pnas.0500613102. [PubMed: 15738415].
  • 9. Wang J, Wu J. Role of miR-155 in breast cancer. Front Biosci (Landmark Ed). 2012;17:2350-5. [PubMed: 22652783].
  • 10. Mangolini A, Ferracin M, Zanzi MV, Saccenti E, Ebnaof SO, Poma VV, et al. Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomark Res. 2015;3:12. doi: 10.1186/s40364-015-0037-0. [PubMed: 26120471].
  • 11. Wang PY, Gong HT, Li BF, Lv CL, Wang HT, Zhou HH, et al. Higher expression of circulating miR-182 as a novel biomarker for breast cancer. Oncol Lett. 2013;6(6):1681-6. doi: 10.3892/ol.2013.1593. [PubMed: 24260062].
  • 12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513-8. doi: 10.1073/pnas.0804549105. [PubMed: 18663219].
  • 13. Kim S, Song JH, Kim S, Qu P, Martin BK, Sehareen WS, et al. Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-beta-mediated MDSC infiltration. Oncotarget. 2016;7(10):11094-112. doi: 10.18632/oncotarget.7150. [PubMed: 26848978].
  • 14. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010;12(6):R90. doi: 10.1186/bcr2766. [PubMed: 21047409].
  • 15. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586-93. doi: 10.1016/j.ygyno.2010.07.021. [PubMed: 20801493].
  • 16. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One. 2012;7(10). e47003. doi: 10.1371/journal.pone.0047003. [PubMed: 23071695].
  • 17. Chen J, Wang BC, Tang JH. Clinical significance of microRNA-155 expression in human breast cancer. J Surg Oncol. 2012;106(3):260-6. doi: 10.1002/jso.22153. [PubMed: 22105810].
  • 18. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1236-43. doi: 10.1158/1055-9965.EPI-12-0173. [PubMed: 22736789].
  • 19. Persson JL. miR-155 meets the JAK/STAT pathway. Cell Cycle. 2013;12(14):2170. doi: 10.4161/cc.25548. [PubMed: 23803728].
  • 20. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28(22):6773-84. doi: 10.1128/MCB.00941-08. [PubMed: 18794355].
  • 21. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010;70(8):3119-27. doi: 10.1158/0008-5472.CAN-09-4250. [PubMed: 20354188].
  • 22. Min M, Peng L, Yang Y, Guo M, Wang W, Sun G. MicroRNA-155 is involved in the pathogenesis of ulcerative colitis by targeting FOXO3a. Inflamm Bowel Dis. 2014;20(4):652-9. doi: 10.1097/MIB.0000000000000009. [PubMed: 24583476].
  • 23. Czyzyk-Krzeska MF, Zhang X. MiR-155 at the heart of oncogenic pathways. Oncogene. 2014;33(6):677-8. doi: 10.1038/onc.2013.26. [PubMed: 23416982].
  • 24. Mignacca L, Saint-Germain E, Benoit A, Bourdeau V, Moro A, Ferbeyre G. Sponges against miR-19 and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers. Cytokine. 2016;82:80-6. doi: 10.1016/j.cyto.2016.01.015. [PubMed: 26841929].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments